Citigroup
ZBIO icon

Citigroup’s Zenas BioPharma ZBIO Stock Holding History

Citigroup’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.94M Buy
72,070
+22,549
+46% +$694K ﹤0.01% 2847
2026
Q2 		$1.26M Buy
49,521
+39,633
+401% +$788K ﹤0.01% 3286
2026
Q1 		$193K Buy
9,888
+7,537
+321% +$169K ﹤0.01% 4019
2025
Q4 		$85.4K Buy
2,351
+2,163
+1,151% +$71.1K ﹤0.01% 4385
2025
Q3 		$4.17K Sell
188
-5,263
-97% -$85.7K ﹤0.01% 5278
2025
Q2 		$52.8K Sell
5,451
-5,359
-50% -$52.2K ﹤0.01% 4730
2025
Q1 		$85.4K Sell
10,810
-1,294
-11% -$10.1K ﹤0.01% 4683
2024
Q4 		$99.1K Buy
+12,104
New +$189K ﹤0.01% 4845

Other funds holding ZBIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
iA Global Asset Management
iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Citigroup's ZBIO Position: Q3 2026 in Review

Citigroup increased its Zenas BioPharma (ZBIO) stake by 46% in Q3 2026, buying an estimated $694K and bringing the position to 72,070 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2847.

Citigroup first reported a position in ZBIO in Q4 2024 and has held it in 8 quarters since. 48 funds tracked by Wall St. Rank hold ZBIO as of Q3 2026.

  • Citigroup held 72,070 shares of Zenas BioPharma worth $1.94M as of Q3 2026.
  • Citigroup bought 22,549 Zenas BioPharma shares in Q3 2026, an estimated $694K.
  • Zenas BioPharma made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2847 holding.
  • Citigroup first reported a position in Zenas BioPharma in Q4 2024 and has held it in 8 quarters since.
  • 48 funds tracked by Wall St. Rank held Zenas BioPharma as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.